Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$76,314.00-0.12%ETH$2,438.71+0.62%GOLD$4,397.10-0.06%OIL$100.92-0.97%
Smart Investors Daily
IR

NASDAQ · IRD

Opus Genetics, Inc.

Healthcare · Biotechnology

$5.41

Down-$0.13 (-2.40%)

Updated Sep 18, 2026, 12:43 AM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
167.86M
P/E ratio
-2.65
Dividend yield
0.00%
52-week range
$1.35 – $7.07
Volume
2.34M
Avg. volume
528.52K

Price performance

IRD price history

1M range · 19 trading sessions · Daily adjusted prices

IRD closed at $5.41 after 19 trading sessions, up 31.31% for the selected period.

Last close
$5.41
Period change
+31.31%
Period low
$3.62
Period high
$6.07
Daily close
View OHLC price history
IRD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$5.80$5.80$5.345$5.412.34M
Sep 15, 2026$5.94$5.95$5.6708$5.821.99M
Sep 14, 2026$6.02$6.22$5.795$5.972.55M
Sep 11, 2026$6.16$6.576$5.77$6.044.66M
Sep 10, 2026$5.87$6.24$5.40$6.076.54M
Sep 9, 2026$5.31$7.07$5.31$5.7354.32M
Sep 8, 2026$4.532$4.6226$4.305$4.342.27M
Sep 4, 2026$4.53$4.80$4.40$4.672.24M
Sep 3, 2026$4.655$4.83$4.28$4.604.43M
Sep 2, 2026$3.86$4.52$3.86$4.455M
Sep 1, 2026$3.65$3.85$3.59$3.83868.85K
Aug 31, 2026$3.71$3.72$3.511$3.62584.22K
Aug 28, 2026$3.85$3.86$3.63$3.69823.65K
Aug 27, 2026$3.80$3.92$3.79$3.85547.54K
Aug 26, 2026$4.17$4.21$3.77$3.80908.74K
Aug 25, 2026$4.07$4.42$4.035$4.111.5M
Aug 24, 2026$4.02$4.2381$3.82$4.03812.17K
Aug 21, 2026$4.16$4.33$4.02$4.051.05M
Aug 20, 2026$4.01$4.26$4.005$4.121.46M

Latest IRD news

The latest Smart Investors Daily articles mentioning IRD.

Stock researchCompany · Overview

IRD research

Overview

Company profile and research snapshot.

Company profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$7.00
Implied upside
—
Analysts
—
IRD recent ratings
DateFirmRatingTarget
Sep 10, 2026WedbushOutperform—
Sep 9, 2026Chardan CapitalBuy—
Sep 9, 2026OppenheimerOutperform—
Sep 9, 2026BTIGBuy—
Sep 9, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 16, 2026

Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?

Opus Genetics, Inc. (NASDAQ:IRD) reported on September 9 that all five low-dose BIRD-1 participants showed clinically meaningful improvement on at least one visual-function measure after treatment with investigational gene therapy OPGx-BEST1. The open-label Phase 1/2 cohort included three participants with Best vitelliform macular dystrophy followed for three months and two with autosomal recessive bestrophinopathy followed […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By